Thomas Ryckewaert

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

Maud Toulmonde, Nicolas Penel, Julien Adam et al. · JAMA Oncology · 2017 · 381 citations · Full text

Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group

Nicolas Penel, Axel Le Cesne, Sylvie Bonvalot et al. · European Journal of Cancer · 2017 · 178 citations

Fibrosis, Surgical Pathology, Pathology +3

Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial

Axel Le Cesne, Jean‐Yves Blay, Julien Dômont et al. · The Lancet Oncology · 2015 · 94 citations

Surgical Oncology, Soft-tissue Sarcoma, Randomised Phase 2 +2

Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial

Jean‐Yves Blay, Sylvie Chevret, Axel Le Cesne et al. · The Lancet Oncology · 2023 · 68 citations

Oncology, Pathology, Ultra-rare Sarcomas +4

Comparison of Response Evaluation Criteria in Solid Tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: A retrospective analysis

S. Taïeb, Esma Saâda-Bouzid, Emmanuelle Tresch et al. · European Journal of Cancer · 2014 · 29 citations

Surgical Oncology, Medicine, Solid Tumours +5